BRCA2 Hereditary Pedigree & Surveillance Protocol Navigator

Clinical Scenario Presets Source-grounded testing profiles

Male

Female

Affected (Cancer Diagnosed)

[+] BRCA2 Positive Pathogenic

[-] BRCA2 Negative True Negative

[?] Untested 50% Mendelian Risk

Surveillance Protocol Navigator (Proband Age: 23) BRCA2 POSITIVE

Personalized risk-calibrated recommendations derived from NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic.

Member: Proband (Alix) Consultand (Gen III)

Genetic Test Status:

Cancer Diagnosis:

Current Age: 23

Lifetime Cumulative Risk Profile

Estimates based on confirmed heterozygous pathogenic BRCA2 mutation

Female Breast Cancer: 45% - 69%

General population baseline: ~12-13%

Ovarian / Fallopian Tube: 11% - 17%

General population baseline: ~1.2%

Pancreatic Cancer: Up to 5% - 10%

Especially with first-degree family history

Melanoma & Prostate (Male): Significantly Elevated

Mendelian Transmission Telemetry

Offspring Transmission Odds:

50% per child from affected heterozygous parent

Autosomal dominant inheritance pattern

Current Screening Phase:

Annual clinical breast exams and baseline clinical evaluation (ages 20-24)

Next Screening Milestone:

Annual high-risk screening breast MRI recommended starting at age 25 (NCCN Guidelines)

Pedigree Members: 5 Verified BRCA2+: 3